Validation of Heart Failure Events in the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Participants Assigned to Doxazosin and Chlorthalidone

Documenti analoghi

• Should Antihypertensive Treatment Recommendations Differ in Patients With and Without Coronary Heart Disease? (From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial [ALLHAT])
  di: Alderman, Michael H., et al.
  Pubblicazione: (2015)
• Cost-effectiveness of Chlorthalidone, Amlodipine, and Lisinopril as First-step Treatment for Patients with Hypertension: An Analysis of the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
  di: Heidenreich, Paul A., et al.
  Pubblicazione: (2008)
• Long-Term Follow-up of Participants with Heart Failure in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
  di: Piller, Linda B., et al.
  Pubblicazione: (2011)
• Blood Pressure Control by Drug Group in the Antihypertensive and Lipid‐Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
  di: Cushman, William C., et al.
  Pubblicazione: (2008)
• Comments on ALLHAT and doxazosin
  di: Krakoff, Lawrence R
  Pubblicazione: (2001)